By: Bryant Furlow From: cancernetwork.com Updates to the National Comprehensive Cancer Network (NCCN) Guidelines® on breast cancer reflect maturing evidence bases and expanding treatment options, including a recently approved immunotherapy regimen for some patients with locally advanced or metastatic disease, according to speakers at the 2019 NCCN Annual Conference, held March 21–23 in Orlando, Florida. “There are many new and emerging options for …
Breast cancer risk among BRCA carriers influenced by timing, number of pregnancies
By: Terry MB, et al. JNCI Cancer Spectr. 2018;doi:10.1093/jncics/pky078. From: healio.com The timing and number of full-term pregnancies appeared to influence the risk for breast cancer among women with BRCA1 or BRCA2 mutations, according to study results published in Journal of the National Cancer Institute Cancer Spectrum. BRCA1 carriers who had only one full-term pregnancy and BRCA2 carriers who had …
Breast ultrasound and cancer detection rates increased under new laws
Source: Blue Cross and Blue Shield Association From: prnewswire.com Breast ultrasound and cancer detection rates increased under new laws State breast density notification laws that mandate reporting of mammogram results can prompt further screening and modestly boost cancer detection rates, say researchers at Yale’s School of Public Health and School of Medicine. Their study was published in the American Journal …
Doctor Robot for You, Real Doctor for Me
By: Marilyn M. Singleton, MD, JD A couple of years ago, computer programs, algorithms, and glorified Google searches were touted as the replacements for a physician’s analysis of a patient’s medical condition. Compressed medical research is quite useful for clinicians who are presented with novel situations and have no readily available colleagues with whom to discuss the case. However, the …
How destroying a tumor promoter could lead to new cancer treatments
By: Catharine Paddock PhD From: medicalnewstoday.com Scientists have cracked a cell mechanism that drives tumor formation in most types of cancer. This finding could lead to much-needed new therapies for cancer, including the hard-to-treat triple-negative breast cancer. The discovery concerns the molecular activity of the tumor suppressor protein p53. This protein sits inside the nucleus of the cell and protects …
Oncoceutics Licenses Rights to ONC201 for Japan to Ohara Pharmaceutical Co., Ltd.
From: didit.com Oncoceutics, Inc. announced today the outlicense of the rights to the company’s lead compound, ONC201, for Japan to Ohara Pharmaceutical Co., Ltd. In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a right of first refusal for the company’s next generation …
New Patient Resource from NCCN Clears up Confusion around Highly Common Type of Skin Cancer
New NCCN Guidelines for Patients: Squamous Cell Skin Cancer explains risk factors and treatment options for cancer type that impacts millions every year. The National Comprehensive Cancer Network® (NCCN®) has published a new book of patient information that explains prevention, diagnosis and treatment for squamous cell skin cancer—the second-most common skin cancer (after basal cell cancer). Squamous cell and basal …
Enzyme USP15 may have potential role in future treatment of various cancers
Source: George Washington University From: sciencedaily.com Researchers at the George Washington University (GW) Cancer Center found that the enzyme USP15 could potentially lead to new treatments for breast and pancreatic cancer. Their findings were published in Nature Communications. “With this study, we validate the role of USP15 in maintaining genome stability and tumor suppression and inform novel treatments for breast …
FDA Approves First Immunotherapy Drug for Triple-Negative Breast Cancer
By: Kristen Fischer From: healthline.com Until now, people with inoperable triple-negative breast cancer had one treatment option: chemotherapy. But this month, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the first immunotherapy treatment for breast cancer. It combines the drug atezolizumab (Tecentriq) with a form of chemotherapy. This development is big news because the drug garnered the …
Challenges, opportunities remain in breast cancer survivorship care
From: healio.com Although significant progress has been made in breast cancer care, challenges and opportunities remain in cancer survivorship, according to a presenter at Miami Breast Cancer Conference. “There are a growing number of breast cancer survivors. It is estimated that there will be more than 18 million cancer survivors in the U.S. alone by 2022, of which 22% are …